Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how the deal fits with the Swiss pharma’s cancer toolkit. The analysts then discuss MHRA CEO Lawrence Tallon’s Guest Commentary in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat of Rep. Diana DeGette (D-Colo.) is a setback for FDA ref...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioCentury This Week
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
Ep. 376 - M&A momentum: 3Q public markets preview
Get summaries like this every morning.
Free AI-powered recaps of BioCentury This Week and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.